Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, causes considerable weight loss, but data are lacking with respect to its effects on cardiovascular outcomes. METHODS In this international, double-blind, randomized, placebo-controlled trial, we randomly assigned, in a 1:1 ratio, 731 patients with heart failure, an ejection fraction of at least 50%, and a body-mass index (the weight in kilograms divided by the square of the height in meters) of at least 30 to receive tirzepatide (up to 15 mg subcutaneously once per week) or placebo for at least 52 weeks. The two primary end points were a composite of adjudicated death from cardiovascular causes or a worsening heart-failure event (assessed in a time-to-first-event analysis) and the change from baseline to 52 weeks in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating better quality of life). RESULTS A total of 364 patients were assigned to the tirzepatide group and 367 to the placebo group; the median duration of follow-up was 104 weeks. Adjudicated death from cardiovascular causes or a worsening heart-failure event occurred in 36 patients (9.9%) in the tirzepatide group and in 56 patients (15.3%) in the placebo group (hazard ratio, 0.62; 95% confidence interval [CI], 0.41 to 0.95; P…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the SUMMIT trial (for tirzepatide) showed a reduction in events regarding time to cardiovascular death or worsening heart failure over 104 weeks (HR 0•62, 0•41-0•95), 79”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [79]
In the citing paper
“Apart from improvements in multiple cardiometabolic risk factors, tirzepatide also improves various obesity-related complications such as obstructive sleep apnoea (OSA), metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction [28–30].”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [30]
In the citing paper
“Both semaglutide and tirzepatide reduce the severity of heart failure with preserved ejection fraction (65, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [66]
In the citing paper
“Tirzepatide also lowers CRP levels in clinical trials in people with heart failure with preserved ejection fraction, or OSA (19, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [66]
In the citing paper
“In the SUMMIT trial (Study of Tirzepatide in Participants With Heart Failure With Preserved Ejection Fraction and Obesity), tirzepatide reduced the risk of the composite of cardiovascular death and worsening HF events.23”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [23]
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669
Self-citationSemaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Kosiborod, M. N., Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Treppendahl, M. B., Verma, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2313917 · Cited by 758
Self-citationPacker, M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.509 · Cited by 656
Self-citationTirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541
The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF
Savji, N., Meijers, W. C., Bartz, T. M., Bhambhani, V., Cushman, M., Nayor, M., Kizer, J. R., Sarma, A., Blaha, M. J., Gansevoort, R. T., et al. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2018.05.018 · Cited by 499
Borlaug, B. A., Jensen, M. D., Kitzman, D. W., Lam, C. S. P., Obokata, M., & Rider, O. J. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvac120 · Cited by 450
Self-citationPaulus, W. J., & Zile, M. R. (2021) · Circulation Research · doi:10.1161/circresaha.121.318159 · Cited by 393
Self-citationKosiborod, M. N., Deanfield, J., Pratley, R., Borlaug, B. A., Butler, J., Davies, M. J., Emerson, S. S., Kahn, S. E., Kitzman, D. W., Lingvay, I., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01643-x · Cited by 308
Self-citation
Cited by
Items 501–600 of 1,086
Heart Failure with Preserved Ejection Fraction
Mathew, D., Elghoul, Y., Bhattacharya, S., & Smith, D. T. (2025) · Medical Clinics of North America · doi:10.1016/j.mcna.2025.04.006 · Cited by 2
Sardà, H., Genua, I., & Miñambres, I. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2025.106951 · Cited by 3
Stefanović, M., Trifunović, D., Mladenović, Z., Tadić, S., Apostolovic, S. R., Petrović, O., Vranić, I., Milic, G., Milovančev, A., Krljanać, G., et al. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133651 · Cited by 2
Tang, H., Zhou, T., Zhang, B., Lu, Y., Kimmel, S. E., Lu, Y., Asch, D. A., & Chen, Y. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.08.359 · Cited by 2
Cardiovascular effects of semaglutide and tirzepatide and their potential for cardioprevention
Cherkashin, D. V., Салухов, В. В., & Khalimov, Y. S. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-323 · Cited by 2
Хроническая сердечная недостаточность
Соболева, Н. И., Петров, В. Н., & Лапотников, В. А. (2025) · doi:10.15862/33mnnpm25 · Cited by 2
Obesity-Related Heart Failure With Preserved Ejection Fraction
Vest, A. R., & Sauer, A. J. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.033 · Cited by 2
Toward a New SUMMIT in Heart Failure with Preserved Ejection Fraction
Felker, G. M. (2025) · New England Journal of Medicine · doi:10.1056/nejme2415551 · Cited by 2
The Win Ratio for Trials for Heart Failure: Academic Desperation or Investigator Decadence?
Packer, M., & Butler, J. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3608 · Cited by 2
Self-citationMcDonough, D. J. (2025) · Physiologia · doi:10.3390/physiologia5010010 · Cited by 3
“…this, we will develop and implement a multi-center randomized clinical trial examining the synergistic e ff ects of low-load/high-repetition resistance exercise with pharmacotherapy-induced weight loss on all-cause hospitalization and mortality in patients with HFpEF and obesity [52,53,139,140].”
Tirzepatide for Heart Failure and Obesity
Marine, J. E., Mandrola, J. M., & Prasad, V. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2502743 · Cited by 2
The Role of GLP-1 Receptor Agonists in Heart Failure
Farkouh, M. E., & Nunes, J. T. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.02.014 · Cited by 3
Packer, M. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102656 · Cited by 2
Self-citationSemaglutide in HFpEF and Obesity
Carbone, S., & Patel, K. V. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102665 · Cited by 2
Inflammation and the Need for Biology-Driven Care in Heart Failure
Sharma, A., Anagnostopoulou, V., & Ducharme, A. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102834 · Cited by 4
Kato, S., Kokita, A., Akanuma, H., Iwamura, S., Takahashi, Y., Kusumi, R., Abe, S., Sasaki, K., Otomo, H., Ando, S., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112913 · Cited by 3
What Is Heart Failure With Preserved Ejection Fraction?
Petrie, M. C., Docherty, K. F., & McMurray, J. J. V. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.09.1596 · Cited by 2
Reddy, Y. N. V., Bergeron, N. P., Carter, R. E., Redfield, M. M., & Borlaug, B. A. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.047295 · Cited by 2
Self-citationKidney dysfunction and pulmonary vascular disease in heart failure with preserved ejection fraction
Amdahl, M. B., Naser, J. A., Tada, A., Doi, S., Harada, T., Ibe, T., Testani, J. M., Melenovský, V., Reddy, Y. N. V., & Borlaug, B. A. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag140 · Cited by 2
Self-citationObesity paradox in coronary heart disease
Lavie, C. J., Catalfamo, V. J., & Carbone, S. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2565094 · Cited by 2
Conde, A. C., Martínez, J. J. G., & Lorite, N. M. (2024) · REC CardioClinics · doi:10.1016/j.rccl.2024.11.004 · Cited by 1
Obésité et insuffisance cardiaque
Isnard, R., Legrand, L., & Pousset, F. (2025) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2024.12.008 · Cited by 1
Al-Shudifat, M., Sumra, B., Kocherry, C., Shamim, H., Jhakri, K., & Khan, S. (2025) · Cureus · doi:10.7759/cureus.78570 · Cited by 5
Alicic, R. Z., & Neumiller, J. J. (2025) · Cardiology Clinics · doi:10.1016/j.ccl.2024.12.003 · Cited by 1
Desai, A., Sharma, S., Siaw, A., Ruiz, J. R., Gómez, V., & GOSWAMI, R. M. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1579218 · Cited by 1
“The summit trial and other studies using GLP1 analogs have demonstrated a 12% – 21% weight loss in HFpEF patients (9, 10).”
Fernandez, M. L. O., Torrigiani, G., Molteni, M., Fortino, I., Cimminiello, C., & Baviera, M. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02674-9 · Cited by 3
“GLP1-RAs could ameliorate HFpEF, as shown in two recent trials [11, 12], but their role in HFrEF is more ambiguous [10].”
Nishikawa, K., Minamisawa, M., Yoshie, K., Suzuki, S., Tanaka, K., Okuma, Y., Kimura, K., Ueki, Y., Oguchi, Y., Kato, T., et al. (2025) · Circulation Reports · doi:10.1253/circrep.cr-25-0041 · Cited by 1
HFpEF Without Obesity: Fallen Off the Radar?
Nelson, A. J., & Pagidipati, N. J. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.05.011 · Cited by 1
Mortality and Economic Impact of Heart Failure
Gillet, A. S., & Stewart, G. C. (2025) · Medical Clinics of North America · doi:10.1016/j.mcna.2025.04.012 · Cited by 1
Schulz, A., Kuttenkeuler, L., Backhaus, S. J., Lange, T., Otto, J., Gronwald, J., Evertz, R., Kowallick, J. T., Hasenfuss, G. P., & Schuster, A. (2025) · European Heart Journal - Imaging Methods and Practice · doi:10.1093/ehjimp/qyaf077 · Cited by 1
Ibe, T., Demmer, R. T., Harada, T., Doi, S., Tada, A., Naser, J. A., Reddy, Y. N. V., & Borlaug, B. A. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3745 · Cited by 2
Self-citationManagement of atrial fibrillation in patients with heart failure with preserved ejection fraction
Rambarat, P. K., DeVore, A. D., Mark, D. B., Bahnson, T. D., & Piccini, J. P. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10536-9 · Cited by 1
Cardiometabolic risk effects of weight‐loss medications: An updated network meta‐analysis
Wang, D., Diao, H., Sun, W., Huan, W., Wang, Y., Ding, L., Cui, W., & Ma, K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16585 · Cited by 3
Störk, S., & Nitschmann, S. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01932-2 · Cited by 1
Role of membrane microdomains in cardiac protection: strategies for diabetic cardiomyopathy
Zemljic‐Harpf, A. E., Bonds, J. A., Zuniga-Hertz, J. P., & Patel, H. H. (2025) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00139.2025 · Cited by 1
Heart Failure in 2025: Update With Perioperative Considerations
Mendapara, P., Ramakrishna, H., & Stawiarski, K. M. (2025) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2025.08.019 · Cited by 1
Evaluation of pulmonary hypertension in heart failure with preserved ejection fraction
Cao, J. J. L., & Reddy, Y. N. V. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10553-8 · Cited by 1
“The dual glucose dependent insulinotropic polypeptide/GLP-1RA agonist, tirzepatide, has also demonstrated comparable clinical benefits to those observed with semaglutide including improved worsening HF risk with improved functional status and quality of life [80, 81].”
Kishimori, T., Kato, T., Wada, A., Tani, A., YAMAJI, R., Koike, J., Iwasaki, Y., Matsumoto, T., Yagi, T., & Okada, M. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.07.026 · Cited by 3
Metabolic syndrome and heart failure
Lopatin, Y. M. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6540 · Cited by 1
Safety and Efficacy of Phentermine and Topiramate for Weight Loss in Obesity-Related HFpEF
MILLER, C. C., Pandey, A., & Litwin, S. E. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.08.027 · Cited by 1
Self-citationDo Heart Failure With Preserved Ejection Fraction Treatments Work by Targeting Adipose Biology?
Borlaug, B. A. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.07.046 · Cited by 1
Self-citationIkigai in aging hearts: Japan’s approach to cardiovascular care
Nakamaru, R., Hara, A., Yamada, Y., Sawano, M., & Yamamoto, K. I. (2025) · Hypertension Research · doi:10.1038/s41440-025-02396-5 · Cited by 1
“…advances in pharmacological therapies for heart failure (HF), such as sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, have contributed to reducing cardiovascular events across a broad range of left ventricular ejection fractions [30, 31].”
Visceral adipose tissue and the female heart: mechanisms and implications
Fahim, M. A., Yao, Y., & Xuan, W. (2025) · Current Opinion in Physiology · doi:10.1016/j.cophys.2025.100871 · Cited by 1
Ahmad, B., Singh, P., Shah, R. J., Arif, M. H., Goel, A., Saeed, M., Saleh, A. O., Amer, S., Mukhlis, M., Waqas, S. A., et al. (2025) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2025.102628 · Cited by 1
Time-to-First Clinical Benefit of Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure
Basile, C., Merolla, A., Mancusi, C., Ambrosino, P., LORENZO, R. D., Rovere, P. Q., & Maggioni, A. P. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.11.489 · Cited by 1
Exercise Rehabilitation for Heart Failure and Associated Cardiomyopathies
Stahl, M. E., Weeldreyer, N. R., MacNamara, J. P., Lozano, P. F. R., & Allen, J. D. (2025) · Current Cardiology Reports · doi:10.1007/s11886-025-02313-9 · Cited by 2
The changing landscape of heart failure: translating management into the modern era
Madaudo, C., Ibrahim, W., Noakes, D., Bromage, D. I., Sinagra, G., McDonagh, T., & Cannata, A. N. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106633 · Cited by 1
Ibrahim, R., Han, W., Wang, W. T., Kau, E., Said, N., Forst, B. J., Pham, H. N., Abdelnabi, M. H., Salih, M., Ali, N. B., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.044577 · Cited by 4
Ma, Z., Lin, Z., Wang, Z., Wu, H., & Dong, Y. (2025) · Asian Heart Journal · doi:10.1097/ah9.0000000000000024 · Cited by 1
Shi, M., Yang, Z., Yin, P., Zhao, H., Li, L., Zhen, Y., Zhao, Q., & Liu, C. (2025) · The International Journal of Cardiovascular Imaging · doi:10.1007/s10554-025-03586-5 · Cited by 1
“Although left ventricular ejection fraction remains normal, patients with HFpEF experience morbidity and mortality rates comparable to those with heart failure with reduced ejection fraction (HFrEF) [1, 2].”
Obesity in Cardiorenal syndrome: Management Opportunities and Challenges
Reaves, A. C., Jaffe, E., & McCallum, W. I. (2025) · Current Hypertension Reports · doi:10.1007/s11906-025-01352-5 · Cited by 1
“The SUMMIT trial showed that participants treated with the dual GLP-1/GIP RA tirzepatide had a lower risk of death from CV causes or worsening HF. [ 40 ]. as these are obesity treatment options for which the most is known about longer-term kidney and CV outcomes.”
Pagnesi, M., Riccardi, M., Maisano, F., Antohi, E., Barberis, V. I., Hamid, M. A., Arfsten, H., Grapsa, J., Karam, N., Muraru, D., et al. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvaf027 · Cited by 1
Rodríguez, J. M. F., Ortiz, M. B. A., Cerrada, J. C., Chivite, D., Romano, P. C., Alonso, R. G., Almorós, A. L., Miramontes‐González, J. P., Rangel, L. S., & Pérez-Silvestre, J. (2026) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2026.502471 · Cited by 1
Indennidate, C., Perencin, B., Maso, V. D., Buda, I., Candido, R., Sinagra, G., & Merlo, M. (2026) · Current Cardiology Reports · doi:10.1007/s11886-025-02340-6 · Cited by 1
“Early data from SUMMIT suggest enhanced cardiometabolic benefits com - pared to selective GLP-1RAs, supporting its potential role in future cardiometabolic risk reduction strategies [66].”
Garin, N., Carballo, D., Dash, J., Stirnemann, J., Reny, J., Vuilleumier, N., & Carballo, S. (2026) · PLoS ONE · doi:10.1371/journal.pone.0341606 · Cited by 2
“The mean percent loss in body weight was 11.6% higher in the tirzepatide arm [15].”
InfluentialVerelst, F. R., Witte, K. K., Ahmed, F. Z., Al‐Khatib, S. M., Parkash, R., Gevaert, A. B., & Spall, H. G. C. V. (2026) · Heart · doi:10.1136/heartjnl-2025-326954 · Cited by 1
“57 As these trials were published after the most recent ESC guidelines, glucagon-like peptide-1 receptor agonists (GLP1RAs) are not included in the recommendations yet, but several RCTs are ongoing ( table 2).”
Ye, B., Xu, Y., Hirashima, F., LeWinter, M. M., van Berlo, J. H., Zile, M. R., & Meyer, M. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag041 · Cited by 1
Self-citationWarden, B. A., Duell, P. B., Bucheit, J. D., & Purnell, J. Q. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.11.013 · Cited by 1
Kim, E. Y., & Feinstein, M. J. (2026) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2026.02.024 · Cited by 5
Cardiometabolic and Diabetes Management in Older Adults
Marion, W., & Neeland, I. J. (2026) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2025.12.005 · Cited by 1
Pharmacological therapy in the obese patient: is it only a matter of fat loss?
Borghi, C., & Bragagni, A. (2026) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suag029 · Cited by 1
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1445 · Cited by 1
Troshina, E. A., Suplotova, L. A., Dzgoeva, F. K., Ekusheva, E. V., Vyuchnova, E. S., Okovityi, S. V., Bakulin, I. G., Бакулина, Н. В., Karonova, T. L., Vagapova, G. R., et al. (2026) · Problems of Endocrinology · doi:10.14341/probl13737 · Cited by 1
Antza, C., Jordan, J., McGowan, B. M., Ciudin, A., Filippi-Arriaga, F., Hönemann, J., Jelacovic, A., Nilsson, P. M., Tsioufis, K. P., Doehner, W., et al. (2026) · Journal of Hypertension · doi:10.1097/hjh.0000000000004285 · Cited by 1
Obesity, metabolic health status, and adverse outcomes in men and women
Ananda, R. A., Solomon, B. D., Nicholls, S. J., & Ray, K. K. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101556 · Cited by 2
“Improved end-organ hard outcomes using these therapies in individuals with obesity and established ASCVD[17], HF with preserved ejection fraction[18,43], MASH or fibrosis[44,45], and CKD,[46] demonstrate the modifiability of multiple health outcomes resulting from obesity.”
Ostrominski, J. W., Schwede, M., Lodi, J., Jirapinyo, P., Spector, D. L., Sheu, E. G., & Platz, E. (2026) · Obesity · doi:10.1002/oby.70173 · Cited by 1
“…in clinical outcomes, HF-related health status, and cardiovascular- kidney-metabolic risk profiles with glucagon-like peptide-1 receptor agonist (GLP-1RA)- based therapies (semaglutide [2.4 mg] and tirzepatide) in persons with obesity and HF with preserved ejection fraction (HFpEF) [3, 4].”
InfluentialMortada, I., Lee, A. W., Quach, V., Rice, J. C., Mansour, S., Chatila, K., Shalaby, M., Blackwell, T. A., & Jneid, H. M. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.03.020 · Cited by 1
The ABCs of cardiovascular disease prevention: communicating what we know in 2026
Goren, L. R., Peng, A. W., Razavi, A. C., Blaha, M. J., Blumenthal, R. S., & Troy, A. L. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101570 · Cited by 2
“Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are the primary option given the cardioprotective effects in patients with and without type 2 diabetes [18 – 20].”
Geagea, M., Kozaily, E., Buchanan, C. J., Litwin, S. E., & Tedford, R. J. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10601-x · Cited by 1
Self-citationKatsura, M., Horiuchi, Y., Tanabe, K., & Wettersten, N. W. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70721 · Cited by 1
“Our observation fits with prior clinical trial data demonstrating broadly similar tolerability profiles, with gastrointestinal symptoms as the predominant adverse effects [7, 13].”
Musa, E. Y. A., & Musa, A. Y. A. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05808-7 · Cited by 1
Obesity and Heart Failure: Introducing the Theme
Monitillo, F., Basile, P., & Lisco, G. (2026) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13040153 · Cited by 2
“…compared to placebo, produces a consistent beneficial effect across all composites of death and worsening heart failure events—analyzed as time to first event (hazard ratios, HRs = 0.41–0.62) [138]—and ameliorated the KCQCSS by 6.9 points, 6 min walk distance by 18.3 m, and EQ-5D-5L by 0.06 [139].”
InfluentialGouda, P., Allyn, N., Belin, R. M., Borentain, M., Butler, J., Curtis, L. H., George, J. T., Hornik, C. P. V., Jackman, J. G., Jessup, M. L., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.102713 · Cited by 2
Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart
Neumann, J., Kirchhefer, U., Hofmann, B., & Gergs, U. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18040447 · Cited by 1
“Tirzepatide was successful to treat chronic diastolic heart failure in patients [148] but may also be tried in sepsis or adriamycin-induced heart failure [149,150].”
Trenas, A., Prieto-Laín, N., Gómez-Hernández, A. I., Velasco, M. Á. P., Bernal-López, M. R., Lopez-Carmona, M. D., de Lucas, M. D. G., Gómez‐Huelgas, R., & Perez-Belmonte, L. M. (2026) · Pharmaceuticals · doi:10.3390/ph19040583 · Cited by 1
“Furthermore, other newly developed drugs such as tirzepatide have been associated with remarkable metabolic benefits in patients with T2DM, obesity, or HF [8,9].”
Heart Failure Guideline-Directed Medical Therapy Scoring Systems: A Scoping Review
Dwivedi, A., Cox, Z. L., Hawkins, N. M., Moghaddam, N., Sidsworth, M., Virani, S., Lee, D. S., & Turgeon, R. D. (2026) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.013881 · Cited by 1
Glucagon-like peptide-1 receptor agonists across anti-inflammation
Chen, D. (2026) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2026.101474 · Cited by 1
Obesity management medications for the surgeon
Harris, M., Mahdi, S., Fairfield, C. J., Brown, L. R., Wadley, M., & Miras, A. D. (2026) · Frontline Gastroenterology · doi:10.1136/flgastro-2025-103307 · Cited by 1
Johansson, E., Wilding, J. P. H., Upadhyay, N., van Hest, N., Kirk, M., Spaepen, E., Zimner‐Rapuch, S., Annemans, L., & Bays, H. E. (2026) · Journal of Medical Economics · doi:10.1080/13696998.2026.2646078 · Cited by 1
Eisa, N., & Barood, O. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.04.014 · Cited by 2
Lee, R. S. M., Seah, J., Baqar, S., Srivastava, P., Levelt, E., Leet, A. S., MacIsaac, A. I., Ekinci, E. I., & MacIsaac, R. J. (2026) · Medicina · doi:10.3390/medicina62050870 · Cited by 2
“A modest but consistent increase in heart rate (2–4 beats per minute) has previously been observed in the GLP-1 RA CVOTs [22,26,31].”
InfluentialHeinzl, M. W., Resl, M., Maier, J., Steinwender, C., Falkensammer, J., Fellinger, P., Steinmaurer, T., Saely, C. H., Hoppichler, F., Stingl, H., et al. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-025-02667-8 · Cited by 1
“Bei knapp der Hälfte der Studienteilnehmer bestand auch ein Diabetes [151].”
Dobrzycka, M., & Karczewska‐Kupczewska, M. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02185-1 · Cited by 3
“In the same trial, with further follow-up, liraglutide showed an 80% reduction in T2D risk compared with the placebo group [113].”
A simplified, tier-based method for clinical evaluation of diastolic function
Argulian, E., Nagueh, S. F., Grapsa, J., & Smiseth, O. A. (2026) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeag123 · Cited by 1
Shin, M. H., Jeong, J. W., Ha, S. E., Singh, R., Lee, M. Y., Ro, S., & Yu, T. Y. (2026) · Pharmaceuticals · doi:10.3390/ph19050791 · Cited by 1
“In the SUMMIT trial, it reduced the composite of cardiovascular death or worsening heart failure events in patients with heart failure with preserved ejection fraction (HFpEF) and obesity [11].”
Singh, V., Wang, M., Ebinger, J., Velazquez, A., Cheng, S. C., Kwan, A. C., & Trivedi, H. D. (2026) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002396 · Cited by 1
Adipokine profile in acute heart failure: associations with natriuretic response and prognosis
Biegus, J., Tymków, R., Iwanek, G., Zymliński, R., Guzik, M., Hurkacz, M., Sopyla, W., Gajewski, P., & Ponikowski, P. P. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag150 · Cited by 1
“20 Therefore, the observed modulation of circulatory volume-pressure overload and systemic inflammation in the study may at least in part be explained by the adipokine-natriuresis interaction.”
吴学碧, Ma, Y., Yin, X., Liu, J., & Zhang, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1863710 · Cited by 1
“In the SUMMIT trial, tirzepatide reduced the composite risk of cardiovascular death or worsening heart failure in patients with obesity-related HFpEF and also improved health status (Packer et al., 2025).”
Saey, S. A., Adel, F., & Chen, H. (2026) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2026.03.025 · Cited by 1
Xie, J., Yang, Y., Chen, W., (45927), L. W., Weng, S., Lyu, Q., & Cao, G. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00722-7 · Cited by 1
Adipose Tissue, Natriuretic Peptides, and HFpEF: Clinical Implications of the Obesity Paradox
Wilk, M. M., & Gajewski, P. (2026) · Biomedicines · doi:10.3390/biomedicines14061305 · Cited by 1
“These medications are actively being studied for their potential role in modifying the metabolic course of HFpEF, which may prove effective by modifying and reducing the AT profile, including the most harmful VAT and its subtype EAT [71,72].”
Loizidis, G., & Summer, R. S. (2026) · Clinical Rheumatology · doi:10.1007/s10067-026-08212-w · Cited by 1
The Impact of Risk Factors and Comorbidities on Heart Failure in the Aging Population
Flores, R. C., Talukder, F. S., & Rabinovich-Nikitin, I. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27125296 · Cited by 1
“In addition, increased aldosterone levels activate cardiac mineralocorticoid receptors driving fibrosis and hypertrophy [124–126].”
Advances in Clinical Cardiology 2025: A Summary of Key Clinical Trials
Todd, M., Savage, P., Campbell, M., Hogg, M., McKane, M., & Menown, I. B. A. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03653-w · Cited by 1
“…composite of CV death or worsening HF (36 vs. 56 patients; HR 0.62; 95% CI 0.41–0.95; p = 0.026) mainly driven by a 56% reduction in worsening HF events (8.0% vs. 14.2%; HR 0.54; 95% CI 0.34–0.85), with improved health status, increased exercise capacity, and an 11.7% greater weight reduction [67].”
InfluentialFan, Y., Chen, X., Cai, X., Dong, Y., Liu, C., Chen, Y., Lip, G. Y. H., & Zhu, W. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156678 · Cited by 1
Packer, M., Butler, J., Ho, J. E., Lam, C. S. P., Petrie, M. C., Schiattarella, G. G., Vaduganathan, M., Zannad, F. M., & Borlaug, B. (2026) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2026.05.016 · Cited by 1
Self-citationYang, D. X., Thakur, S., Akunor, H., Stacey, R. B., & Upadhya, B. (2026) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13070291 · Cited by 2
“Recently, treatment with tirzepatide (a long-acting agonist of glucose-dependent insulinotropic polypeptide and GLP-1R) led to a lower risk of a composite of death from CV causes or HF hospitalization and improved health status in patients with CM-HFpEF [117].”
Gómez-Martín, Á., Marqués, P., Recatalá, C. A., Vea, À., Domingo, E., Alabadí, B., Real, J. T., Sanz, M., & Piqueras, L. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108321 · Cited by 2
Khan, I., Meenakshi, S., Abubakar, M., Kumar, N., Gaikwad, V. L., Rai, A., & Murti, K. (2026) · Endocrine · doi:10.1007/s12020-026-04686-5 · Cited by 2
Kokura, Y., Kishimori, T., Kato, T., Iwasaki, Y., Wada, A., Tani, A., Yamaji, R., Koike, J., Matsumoto, T., Yagi, T., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113404 · Cited by 1
Metadata
- Authors
- Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ge, J., Weerakkody, G. J., Ou, Y., Bunck, M. C., Hurt, K. C., Murakami, M., & Borlaug, B. A.
- Affiliations
- Cleveland Clinic (US)
- From Baylor University Medical Center, Dallas (M.P.); Imperial College, London (M.P.); RHJ Department of Veterans Affairs, Health System and Medical University of South Carolina, Charleston (M.R.Z., S.E.L.); the Cardiovascular Division, Department of Medicine, University of Virginia Health System, Charlottesville (C.M.K.); Flourish Research, Boca Raton, FL (S.J.B.); the Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland (V.M.); the Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China (J.G.); Eli Lilly, Indianapolis (G.J.W., Y.O., M.C.B., K.C.H., M.M.); and the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-01-30
- Volume
- 392
- Issue
- 5
- Pages
- 427-437
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4404437149
- Semantic Scholar
- aeedfcfb5543cef26bd4f4576e1c5a59b4d2424f
- Cited by
- 1,009
- References
- 30
- Citations by year
- 2026: 496 · 2025: 494
- FWCI
- 303.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company (N/A)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- tirzepatide, heart failure with preserved ejection fraction, obesity, GIP/GLP-1 receptor agonist, weight loss, cardiovascular mortality, worsening heart failure, Kansas City Cardiomyopathy Questionnaire, quality of life, body mass index, GLP-1 receptor agonists, GIP receptor agonist, cardiovascular outcomes, weight loss treatment, heart failure with reduced ejection fraction
- MeSH terms
- Tirzepatide, Aged, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Humans, Male, Middle Aged, Obesity, Quality of Life, Stroke Volume, Weight Loss, Body Mass Index, Treatment Outcome, Glucagon-Like Peptide 1, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.